Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally approved for type 2
diabetes mellitus, have demonstrated efficacy in reducing cardiovascular events, particularly …

Patients with multiple myeloma (MM) were among the groups impacted more severely by the
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …

Sodium–glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and
approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic …

Carfilzomib is an irreversible proteasome inhibitor used for multiple myeloma patients.
However, carfilzomib treatment is associated with cardiovascular complications …

Background Carfilzomib (CFZ) is a second-generation proteasome inhibitor used to treat
multiple myeloma. Potent inhibition of the proteasome results in chronic proteotoxic …

Thrombosis represents a frequent and potentially severe complication in individuals
diagnosed with multiple myeloma (MM). These events can be driven by both the disease as …

Background: Controversy persists regarding the effects of sodium-glucose cotransporter 2
(SGLT2) inhibitors on cancer. The underlying causal relationship remains unclear. Method …

Background Currently, most patients with cardiac arrest (CA) show reversible myocardial
dysfunction, hemodynamic instability, systemic inflammation and other pathophysiological …

The goal of the second volume of this Special Issue was to build upon the success of the first
one and to continue to highlight the ever-expanding list of pharmacological properties of the …

The goal of this Special Issue is to highlight the ever-increasing progress in pharmacological
research on sodium-glucose co-transporter (SGLT) type 2 (SGLT2) inhibitors or gliflozins …